Tsuji Shunya, Mizukami Sora, Sakamoto Akihiko, Takemoto Kenji, Seto Tetsuya, Uehara Kazuya, Yukata Kiminori, Sakai Takashi, Iwaisako Keiko, Takeda Norihiko, Yanai Ryoji, Asagiri Masataka
Department of Pharmacology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, Japan.
Research Institute for Cell Design Medical Science, Yamaguchi University, Minami-Kogushi, Ube, Yamaguchi, Japan.
Sci Rep. 2025 Feb 20;15(1):6197. doi: 10.1038/s41598-025-89988-w.
Osteoclasts are specialized cells essential for bone resorption, a crucial process in bone remodeling, and dysregulation of osteoclastogenesis can lead to pathological bone loss such as osteoporosis and rheumatoid arthritis. Therefore, understanding the precise mechanisms governing osteoclast differentiation is crucial for developing effective therapies for skeletal diseases. In osteoclastogenesis, as well as other differentiated cells, it is well understood that cell cycle arrest is essential for terminal differentiation and is tightly regulated by CDK inhibitors such as Cip/Kip family and Ink4 family protein. In this manuscript, we identified p15, a member of the Ink4 family, as a novel regulator of osteoclastogenesis by comprehensive single-cell RNA sequence data reanalyzing. Furthermore, histological analysis and in vitro osteoclast differentiation assay revealed that p15 functionally regulates osteoclastogenesis. Our findings may not only provide insights into the molecular mechanisms of osteoclast differentiation but also underscore the potential of harnessing cell cycle mechanisms to develop novel therapeutic strategies for bone diseases.
破骨细胞是骨吸收所必需的特化细胞,骨吸收是骨重塑中的一个关键过程,破骨细胞生成失调可导致骨质疏松症和类风湿性关节炎等病理性骨质流失。因此,了解调控破骨细胞分化的精确机制对于开发骨骼疾病的有效治疗方法至关重要。在破骨细胞生成过程中,与其他分化细胞一样,众所周知,细胞周期停滞对于终末分化至关重要,并且受到Cip/Kip家族和Ink4家族蛋白等CDK抑制剂的严格调控。在本手稿中,我们通过全面的单细胞RNA序列数据重新分析,确定Ink4家族成员p15是破骨细胞生成的新型调节因子。此外,组织学分析和体外破骨细胞分化试验表明,p15在功能上调节破骨细胞生成。我们的发现不仅可能为破骨细胞分化的分子机制提供见解,还强调了利用细胞周期机制开发骨骼疾病新治疗策略的潜力。